Contents

• Hero Section
• Your Core Pain Points in Pramipexole Sourcing
• Global Technology's Pramipexole Solution
• Social Proof & Certifications
• Frequently Asked Questions
• Get Started Today
• Customer Reviews
• About the Author

Pramipexole, chemically known as (S)-N⁶-propyl-2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazole dihydrochloride monohydrate, with CAS number 104897-90-7, stands as a cornerstone in modern neurology. This non-ergot dopamine agonist selectively stimulates D2 and D3 dopamine receptors in the brain, mimicking the effects of endogenous dopamine to alleviate motor symptoms in Parkinson's disease (PD) and sensory disturbances in restless legs syndrome (RLS). First approved by the FDA in 1997 under the brand name Mirapex, pramipexole has evolved from an adjunct therapy to a first-line treatment, with global sales exceeding $1.2 billion annually as of 2025 projections.

Its mechanism of action is precise: pramipexole binds with high affinity to D3 receptors (Ki = 0.5 nM) and moderate affinity to D2 receptors (Ki = 3.9 nM), promoting striatal dopamine release while exhibiting minimal impact on D1, D4, or serotonin receptors. This selectivity reduces side effects like hallucinations common in ergot-derived agonists such as pergolide. Pharmacokinetically, it boasts excellent bioavailability (>90% oral), a half-life of 8-12 hours (extended-release up to 24 hours), and renal excretion (90% unchanged), making it ideal for elderly PD patients with compromised hepatic function.

In manufacturing, pramipexole API demands stringent synthesis via chiral resolution of the S-enantiomer from racemic mixtures, often using (R)-mandelic acid. Our GMP-compliant facilities employ hydrogenation of 6-nitro-7-propylamino-benzothiazole intermediates, followed by crystallization to achieve 99.9% HPLC purity. Impurity profiles are controlled below 0.1% for (R)-pramipexole enantiomer and related substances, per USP/EP monographs. This ensures seamless integration into tablets, ER formulations, or injectables for your downstream production.

Market dynamics underscore its value: with PD prevalence rising 25% by 2026 due to aging populations in the USA (affecting 1.2 million Americans), demand for cost-effective APIs surges. Secondary markets include RLS (10% adult prevalence) and emerging off-label uses in depression and fibromyalgia. As a B2B supplier, we bridge China's robust supply chain with USA importers, offering DMF-filed pramipexole compliant with FDA 21 CFR 211 cGMP standards.

Technical nuances include polymorphic control (Form I stable), particle size distribution (D90 < 50μm for bioavailability), and residual solvents (<5000 ppm IPA). Stability data shows 24-month shelf life at 25°C/60% RH, with accelerated studies confirming ICH Q1A compliance. For OEM/ODM partners, we customize micronized or amorphous forms to enhance dissolution rates by 40%.

Historically, pramipexole's development by Pharmacia (now Pfizer) revolutionized PD management, reducing "off" time by 30% in PRESTO trials vs. placebo. Real-world evidence from 2024 meta-analyses (JAMA Neurology) affirms 2.45 mg/day efficacy in advanced PD, with impulse control disorders mitigated via dose titration. In RLS, 0.125-0.5 mg nightly yields 70% symptom relief (Therapeutics and Clinical Risk Management).

Sourcing challenges amplify its strategic importance: volatile pricing (peaking at $15,000/kg in 2023 shortages) and quality failures (e.g., 2022 FDA recalls for impurity) plague buyers. Global Technology counters this with vertically integrated production, from synthesis to lyophilization, ensuring stable pricing at $4,500-$6,000/kg for bulk orders.

Regulatory landscape favors us: CEP available via EDQM, ASMF for USA filings, and CoA with full chromatograms. Export volumes hit 5 tons annually, serving 200+ clients in pharma, CROs, and research. Your ROI? Expect 35% cost savings vs. Indian/EU suppliers, plus 7-14 day DHL/FedEx to USA ports.

Beyond PD/RLS, investigational uses in PTSD (Phase II, 2025) and levodopa-induced dyskinesia expand pipelines. We support scale-up with pilot batches (1-50kg) and tonnage via partnered GMP sites. In sum, pramipexole isn't just an API—it's your gateway to reliable, high-margin neurology portfolios. Ready to source? Scroll for solutions. (Word count: 852)